Enanta Pharmaceuticals Stock Price - ENTA

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Enanta Pharmaceuticals Inc ENTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.12 -0.23% 53.20 52.76 54.53 53.25 53.32 16:43:46
Bid Price Ask Price Spread Spread % News
43.44 54.00 10.56 19.56% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,316 210,519 $ 53.40 $ 11,242,477 219,411 51.00 - 106.80
Last Trade Time Type Quantity Stock Price Currency
16:12:32 average 14,600 $ 53.20 USD

Enanta Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.06B 19.92M $ 71.96M 2.22 32.90 18.80M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Enanta Pharmaceuticals News

Loading Messages....

Latest ENTA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ENTA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week52.5854.5351.2952.93153,6190.621.18%
1 Month56.1258.3851.0053.70180,035-2.92-5.2%
3 Months63.5267.8851.0059.00189,036-10.32-16.25%
6 Months72.7973.9851.0061.61186,979-19.59-26.91%
1 Year100.30106.8051.0075.21189,183-47.10-46.96%
3 Years29.25127.7727.24172.08207,70923.9581.88%
5 Years35.90127.7716.7553.65228,41217.3048.19%

Enanta Pharmaceuticals Description

Enanta Pharmaceuticals Inc is an American biotechnology company focused on research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Your Recent History
Enanta Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.